Expanded Access Program Results Film
Paradigm (ASX:PAR) reports: 65% pain reduction in osteoarthritis patients treated under the US FDA expanded access program. The program treated 10 retired NFL players.
0
likes
•
0
questions
•
0
company answers
Ask a question
Your question will be sent privately to Paradigm Biopharmaceuticals. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Paradigm Biopharmaceuticals a question about this update.